Table 2 Adjusted Cox multivariate analyses of prognostic factors for the matched cohort
Endpoint | Variable | P value | HR | 95% CI |
|---|---|---|---|---|
OS | Gender (male vs. female) | 0.334 | 0.62 | 0.24–1.63 |
Age (≤ 50 vs. > 50 years) | 0.175 | 1.63 | 0.80–3.30 | |
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) | 0.766 | 1.12 | 0.54–2.29 | |
T stage (T1–2 vs. T3–4) | 0.393 | 1.54 | 0.57–4.12 | |
N stage (N0–1 vs. N2–3) | 0.022 | 2.26 | 1.12–4.53 | |
Clinical stage (II–III vs. IV) | 0.134 | 1.86 | 0.83–4.18 | |
Concurrent chemotherapy (docetaxel vs. cisplatin) | 0.802 | 0.92 | 0.46–1.83 | |
DMFS | Gender (male vs. female) | 0.885 | 0.95 | 0.48–1.88 |
Age (≤ 50 vs. > 50 years) | 0.901 | 0.96 | 0.52–1.79 | |
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) | 0.039 | 1.85 | 1.030–3.31 | |
T stage (T1–2 vs. T3–4) | 0.600 | 1.22 | 0.59–2.51 | |
N stage (N0–1 vs. N2–3) | 0.017 | 2.01 | 1.14–3.58 | |
Clinical stage (II–III vs. IV) | 0.530 | 1.27 | 0.61–2.64 | |
Concurrent chemotherapy (docetaxel vs. cisplatin) | 0.827 | 1.07 | 0.60–1.88 | |
LRFS | Gender (male vs. female) | 0.146 | 1.85 | 0.81–4.21 |
Age (≤ 50 vs. ≥ 50 years) | 0.986 | 0.99 | 0.41–2.42 | |
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) | 0.852 | 0.92 | 0.39–2.17 | |
T stage (T1–2 vs. T3–4) | 0.418 | 1.58 | 0.52–4.79 | |
N stage (N0–1 vs. N2–3) | 0.128 | 1.86 | 0.84–4.13 | |
Clinical stage (II–III vs. IV) | 0.278 | 0.65 | 0.29–1.45 | |
Concurrent chemotherapy (docetaxel vs. cisplatin) | 0.288 | 0.65 | 0.29–1.45 | |
NRFS | Gender (male vs. female) | 0.337 | 0.55 | 0.16–1.88 |
Age (≤ 50 vs. > 50 years) | 0.146 | 0.40 | 0.12–1.38 | |
Pretreatment EBV DNA (< 4000 vs. ≥ 4000 copies/mL) | 0.171 | 1.86 | 0.77–4.52 | |
T stage (T1–2 vs. T3–4) | 0.491 | 0.72 | 0.28–1.86 | |
N stage (N0–1 vs. N2–3) | 0.334 | 1.55 | 0.64–3.77 | |
Clinical stage (II–III vs. IV) | 0.783 | 0.81 | 0.18–3.71 | |
Concurrent chemotherapy (docetaxel vs. cisplatin) | 0.036 | 0.34 | 0.12–0.93 |